Literature DB >> 15518681

Paid organ procurement: pragmatic and ethical viewpoints.

A S Daar1.   

Abstract

None of the familiar arguments against paid organ procurement really works. Most arguments spring from revulsion that arises from the abuses of the practice rather than the act itself. This has not stopped official condemnation. However, the evidence we have at present is that such condemnation, aimed at correcting a perceived moral wrong rather than at abuses of a practice (the correction of which might actually bring some moral good), has utterly failed, and many more countries including the United States now harbor paid organ procurement. We can try to develop and articulate a truly compelling moral argument against paid organ procurement or we can try to minimize the harm that comes out of this practice. Since it is unlikely that all countries will agree on a standardized approach in such a muddled field, the best way may be to let every country decide on what is best for itself. Some may want to ban the practice using legislation. Others may want to try regulating the practice, knowing full well that they cannot stop it and that turning a blind eye to the practice, or simply condemning it, does no good whatsoever and actually increases the harm because everything is done underground, with middlemen and mafia-like organizations making a lot of money out of a lot of misery. Some countries may choose to find other, more innovative solutions. We call attention to an important resolution dealing with this subject at the December 2002 ethics and transplantation congress in Munich.

Keywords:  Health Care and Public Health

Mesh:

Year:  2004        PMID: 15518681     DOI: 10.1016/j.transproceed.2004.08.128

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Compensated living kidney donation: a plea for pragmatism.

Authors:  Faisal Omar; Gunnar Tufveson; Stellan Welin
Journal:  Health Care Anal       Date:  2009-01-29

2.  Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Authors:  Andreas K Nussler; Katrin Zeilinger; Lilianna Schyschka; Sabrina Ehnert; Jörg C Gerlach; Xueying Yan; Serene M L Lee; Maren Ilowski; Wolfgang E Thasler; Thomas S Weiss
Journal:  J Mater Sci Mater Med       Date:  2011-04-03       Impact factor: 3.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.